Full-Time
Provides core photonics for medical tech
No salary listed
North Syracuse, NY, USA + 1 more
More locations: Irvine, CA, USA
In Person
See people who can refer or advise you
Novanta designs and supplies core technology platforms for precision photonics used in medical devices and advanced industrial equipment. Its products are components and subsystems—such as lasers, optics, sensors, and imaging hardware—that OEMs integrate into their own machines. Unlike companies that sell end-user devices, Novanta focuses on providing the underlying photonics technology that OEMs build into products, enabling reliable performance and scalable manufacturing. The company differentiates itself through deep specialization in photonics and by growing through acquisitions, aligning its portfolio toward medical technology and precision industrial markets. Its goal is steady, long‑term growth by delivering proven core technologies that help customers develop better medical devices and industrial solutions.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Bedford, Texas
Founded
1968
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Performance Bonus
Experts call FCC's block on foreign robotics a nearshoring tactic. While cyberthreats are a growing risk to national security, the agency's sweeping block on humanoids, quadrupeds and mobile robot imports could reinvigorate domestic suppliers. Published Aug. 18, 2026 First published on Following the Trump administration's move last month to block the sale of advanced industrial robots from all countries outside of the United States, experts are mixed on the outcome but ultimately supportive of what this could mean from a supply standpoint. The Federal Communications Commission on July 28 updated its covered list to include imports of mobile robots, such as humanoids and quadrupeds, as well as connected power inverters, citing national security risks. Products meeting those definitions can no longer receive FCC equipment authorization and cannot be imported, marketed or sold in the U.S., making them essentially banned. Affected companies can apply for a conditional approval. The sweeping action, which immediately took effect, came amid growing concern over China's ability to surveil customers and obtain sensitive data around the world from devices assembled in the country. However, it also looks to address another issue entirely - the U.S. falling behind globally in terms of robot production and deployment. "Domestically, we need help," Robert Little, a business development advisor and former chief of robotics strategy at Novanta, said. At first glance, Little said he thought the move was necessary for cybersecurity reasons. But after looking at the FCC's similar action regarding drones and drone parts, he said the recent ban was also a mechanism to drive domestic production of humanoids and mobile robots, as well as incentive for foreign suppliers to build their supply chains in the U.S. "That's its ultimate purpose," Little said. "And I think it can be effective." The U.S. is considered one of the global robotics leaders when it comes to investor capital, fueled by surging interest in AI, foundation model research and robotics systems. U.S.-headquartered companies such as Figure AI, Agility Robotics and Tesla received 52% of the $9.4 billion in global venture capital deployed last year, according to the Robotics Center of Silicon Valley. However, there is a widening gap between the number of robots manufactured by U.S. companies versus Chinese competitors. China installed 295,000 robots in 2024, representing more than half of the world's market share, according to the International Federation of Robotics. While preliminary 2025 numbers have not been released yet for China, the group estimated that installations are about ten times higher than the U.S. In other words, the "U.S. leads the world in where robotics is heading...while losing the race on where robotics is shipping today," the Robotics Center of Silicon Valley said in its 2026 report. To address the issue, the Association for Advancing Automation has urged Congress to consider adopting a national robotics strategy that includes subsidies, tax incentives and other means to drive domestic adoption and production of U.S. robots. The FCC's move, which only applies to new products, creates a runway for domestic companies to become more competitive, Little said. Then if the restrictions are lifted in the next few years, "they'll be in a much better place." Erik Nieves, founder and CEO of Plus One Robotics, said he knew the Trump administration would put restrictions on China's robots but was surprised by the breadth of the FCC's ban. Rather than just targeting China, the move affected robotics from all other countries, including trade partners such as Japan, Germany and South Korea. "We would have preferred to see it be more circumspect, but you don't control what the government does," Nieves said. "If it's true that every action is an overreaction, that's what this is." He also pointed out that the impact of the ban depends on the complexity of the conditional approval from the U.S. Department of Defense. Nieves said the details are unclear about the exemption process, adding that if it's more than just a simple check, then the U.S. could be "excessively hampering partners that we really would not rather do that to." Some say the ban doesn't go far enough. In a recent LinkedIn post, Standard Bots CEO Evan Beard said that fixed industrial robot arms should be part of the FCC's covered list because, similar to mobile robots, they have a networked, sensing, actuated system and raise security risks.
Novanta reported second-quarter revenue of $265.8 million, beating analyst estimates of $262.3 million with 10.3% year-on-year growth. The medical technology company also exceeded expectations on adjusted earnings per share ($0.89 versus $0.83 estimated) and adjusted EBITDA ($60.73 million versus $58.88 million estimated). CEO Matthijs Glastra attributed the performance to organic growth across all business units, driven by increased demand in precision robotics, AI-driven manufacturing, and minimally invasive surgery. New product revenue jumped more than 50% year-on-year. The company raised its full-year revenue guidance to $1.14 billion at the midpoint from $1.05 billion, an 8.4% increase. Management also lifted adjusted earnings guidance to $3.71 per share at the midpoint. During the earnings call, analysts questioned humanoid robotics deployments, Gen AI data centre exposure, and core gross margin evolution.
Novanta reported strong second-quarter results with 9% organic sales growth, 16% adjusted EBITDA increase, and 17% adjusted earnings per share growth. Adjusted gross margin expanded to 47%, whilst operating cash flow reached $65 million, bringing year-to-date cash flow to $117 million. The Automation Enabling Technologies segment led growth with 12% higher revenue and 18% bookings increase. Generative AI-related applications represented approximately 17% of revenue and grew roughly 25%. The company also received its first major servo-drive orders for humanoid robot development. Following the Riverpoint Medical acquisition closure, Novanta raised its 2026 outlook. The company now expects revenue of $1.13 billion–$1.14 billion, adjusted EBITDA of $273 million–$278 million, and adjusted EPS of $3.68–$3.74.
Novanta, a medicine and manufacturing technology provider, reported second-quarter revenue of $265.8 million, beating analyst estimates of $262.3 million and marking 10.3% year-on-year growth. The company's non-GAAP earnings of $0.89 per share exceeded expectations by 7.2%. Novanta raised its full-year revenue guidance to $1.14 billion at the midpoint, up from $1.05 billion—an 8.4% increase. The company also lifted its full-year adjusted EPS guidance to $3.71 and EBITDA guidance to $275.5 million, above analyst estimates of $247.3 million. Next quarter's revenue guidance of $302 million came in 14.9% above analyst expectations. Free cash flow margin improved to 21.6% from 4.8% in the same quarter last year, though operating margin declined to 6.8% from 11.4%.
Novanta announced its financial results for the second quarter of 2026, reporting GAAP revenue of $266 million, a 10% increase year-over-year. The medical and advanced technology equipment manufacturer achieved organic revenue growth of 9%, marking its strongest quarter since the first quarter of 2023. GAAP net income reached $13 million, whilst adjusted EBITDA rose 16% to $61 million. GAAP diluted earnings per share stood at $0.30, compared to $0.12 in the prior year. Adjusted diluted EPS increased 17% to $0.89. Chair and CEO Matthijs Glastra highlighted the company's performance, noting it exceeded expectations across revenue, margins, and profitability, with an adjusted EBITDA margin of 23%.